CD163 followed the same pattern, with greater CD163 expression in alveoli and vessels from patients with COPD and NSCLC than patients with GOLD 1–2 COPD, NS, and smokers (Fig. 3G,H). Here, CD163 is linked to non-small cell lung carcinoma.